Loading stock…

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Rhythm Pharmaceuticals, Inc.

RYTMMarket cap $6.25BPrice $90.8

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops treatments for rare genetic obesity disorders caused by faulty brain signaling. Its drug Imcivree is the first FDA-approved therapy targeting the actual root cause of hunger in conditions like POMC deficiency, not just the symptoms.

In Bastion Portfolios?

52W Return-18%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+100%10

Revenue Forecast

Rev CAGR (1y)+65%10

Rev CAGR (3y)+65%10

Rev CAGR (5y)+53%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-84%1

Net Income Margin-86%1

Free Cash Flow Margin-44%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-408%1

ROA-51%1

Earnings Stabilityna–

GEAR+VERY WEAK13

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)282

P/BV60.71

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-1.7%2

Dividend Yieldna–

Momentum

Short term

1 month return-12%2

3 month return-21%2

YTD return-15%3

Mid term

Price vs 52wHigh74%4

1 year return-9%3

Long term

3 year return+288%10

5 year return+667%10

Risk Shield

Price Risk

Beta1.81

Volatility46%3

Free Cash Flow

Free Cash Flow Margin-44%1

Free Cash Flow Yield-1.7%2

Quality

ROCE-72%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

RYTMRhythm Pharmaceuticals

Revenue FY25$190M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+100%10

Revenue, next 1Y+65%10

Revenue, next 3Y, CAGR+65%10

Revenue, next 5Y, CAGR+53%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 100%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 65%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 53%/yr over five years.10/10

WATCH

Revenue grew 100%/yr over the last 3 years; forecasts see it cooling to 65%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-12%2

3-month return-21%2

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return-9%3

3-year return+288%10

5-year return+667%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +288% over three years and +667% over five, ahead of 90% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 9% over the past year, now 26% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-12%), over three months (-21%) and so far this year (-15%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Rhythm Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RYTMRhythm Pharmaceuticals

Revenue FY25$190M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+100%10

Revenue, next 1Y+65%10

Revenue, next 3Y, CAGR+65%10

Revenue, next 5Y, CAGR+53%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 100%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 65%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 53%/yr over five years.10/10

WATCH

Revenue grew 100%/yr over the last 3 years; forecasts see it cooling to 65%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-12%2

3-month return-21%2

YTD return-15%3

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return-9%3

3-year return+288%10

5-year return+667%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +288% over three years and +667% over five, ahead of 90% of the market.

WATCH

None flagged.

WEAKNESSES

It's down 9% over the past year, now 26% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-12%), over three months (-21%) and so far this year (-15%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Rhythm Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community